Evaluation of Recombinant Replication-Defective Adenoviruses Which Induce Anti-Viral Activity in Cattle
Foreign Animal Disease Research
2013 Annual Report
1a.Objectives (from AD-416):
Foot-and-Mouth Disease Virus (FMDV) is a contagious, economically devastating viral infection of cloven-hooved animals. Susceptible animals can be protected from the disease by vaccination; however it takes approximately seven days to induce immune protection. Rapid-acting biotherapeutics are needed to provide protection prior to the onset of infection. One class of biotherapeutic candidates, the Adenovirus 5-vectored interferon (Ad-IFN) has been show to induce short-lived resistance against FMDV. This research project seeks to evaluate different classes and subclasses of interferons which enhance the anti-FNDV activity and assess their potential use as new biotherapeutic candidates.
Speciific objectives include:
1. Construct plasmid vectors containing bovine type I interferons and other host genes for in vitro testing and produce recombinant adenoviruses for in vitro and in vivo testing.
2. Test the anti-FMDV activity in vitro and in animals treated with the recombinant adenoviruses.
1b.Approach (from AD-416):
1. Bovine genes will be cloned, including type I interferons, into plasmid vectors, expressed and the anti-FMDV activity of the expressed proteins will be tested in bovine cell lines and tested for efficacy in-vitro against FMDV.
2. Recombinant adenoviruses will be constructed and produced using the most effective plasmid vectors generated in the in vitro testing.
3. Animal trials will be conducted at KSU, without challenge, to test the antiviral activity in the sera of animals treated with the recombinant adenoviruses.
4. The sera generated from the animal studies will be tested for antiviral activity against FMDV at ARS, PIADC.
In FY 2013 a post-doctoral fellow from KSU and has been working in at ARS, PIADC, where he and ARS staff have tested several methods and found that eight strategies increased the production or activity of interferons in cell culture.
No technologies were transferred or publications produced in FY 2013.